• 1
    Cawthorn SJ, Parums DV, Gibbs NM, A'Hern RP, Caffarey SM, Broughton CIM, Marks CG. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet. 1990; 1: 10559.
  • 2
    Hermanek P, Henson DE, Hutter RVP, Sobin LH, eds. UICC TNM supplement. New York: Springer, Berlin Heidelberg, 1993.
  • 3
    Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42: 16773.
  • 4
    Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis. 2001; 16: 298304.
  • 5
    Steel MC, Woods R, Mackay JM, Chen F. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. Anz J Surg. 2002; 72: 4837.
  • 6
    Miyoshi M, Ueno H, Hashiguchi Y, Mchizuki H, Talbot IC. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg. 2006; 243: 4927.
  • 7
    Katsumata D, Fukui H, Ono Y, Ichikawa K, Tomita S, Imura J, Abe A, Fujita M, Watanabe O, Tsubaki M, Sunagawa M. Depth of tumor invasion in locally advanced rectal cancer correlates with patients' prognosis: the usefulness of elastic stain for its measurement. Surg Today. 2008; 38: 11522.
  • 8
    Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008; 28: 17738.
  • 9
    Tokoro T, Okuno K, Hida J, Ishimaru E, Ueda K, Yoshifuji T. Depth of mesorectal invasion has prognostic significance in T3N0 low rectal cancer. Hepato-Gastroenterology. 2009; 56: 1247.
  • 10
    Bori R, Sejben I, Svébis M, Vajda K, Markó L, Pajkos G, Cserni G. Heterogeneity of pT3 colorectal carcinomas according to the depth of invasion. Pathol Oncol Res. 2009; 15: 52732.
  • 11
    Pollheimer MJ, Kornprat P, Pollheimer VS, Lindtner RA, Schlemmer A, Rehak P, Langer C. Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int J Colorectal Dis. 2010; 25: 18796.
  • 12
    Picon AI, Moore HG, Sternberg SS, Minsky BD, Paty PB, Blumberg D, Quan SH, Wong WD, Cohen AM, Guillen JG. Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis. 2003; 18: 48792.
  • 13
    Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986; 1: 147982.
  • 14
    Kanehara & Co. Ltd. Japanese Society for Cancer of the Colon and Rectum (JSCCR). Japanese classification of colorectal carcinoma, 2nd English edn. Tokyo: Kanehara & Co. Ltd., 2009.
  • 15
    Sobin LH, Gaspodarowicz MK, Wittekind C. TNM classfication of malignant tumors, 7th ed. New York: Wiley-Blackwell, 2009.
  • 16
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual, 7th edn. New York, NY: Springer, 2010.
  • 17
    Shirouzu K, Akagi Y, Fujita S, Ueno H, Takii Y, Komori K, Ito M, Sugihara K. Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study. Ann Surg. 2011; 253: 70410.
  • 18
    Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995; 181: 33546.
  • 19
    Law WL, Ho JWC, Chan R, Au G, Chu KW. Outcome of anterior resection for Stage II rectal cancer without radiation-the role of adjuvant chemotherapy. Dis Colon Rectum. 2005; 48: 21826.
  • 20
    Zaheer S, Pemberton JH, Farouk R, Dozois RR, Wolff BG, Listrup D. Surgical treatment of adenocarcinoma of the rectum. Ann Surg. 1998; 227: 80011.
  • 21
    Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SHQ, Wong D, Cohen AM. T3N0 rectal cancer-results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg. 1999; 3: 6427.
  • 22
    Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997; 336: 9807.
  • 23
    Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJT, Pahlman L, Glimelius B, van Krieken JHJM, Leer JWH, van de Velde CJH. (The Dutch Colorectal Cancer Group) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345: 63846.
  • 24
    Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg. 2003; 90: 35564.
  • 25
    Mercury study group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the Mercury Study. Radiology 2007: 243: 1329.
  • 26
    Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, Shirouzu K, Muto T. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis colon Rectum. 2006; 49: 166372.
  • 27
    Moriya Y, Sugihara K, Akasu T, Fujita S. Importance of extended lymphadenectomy with node dissection for advanced lower rectal cancer. World J Surg. 1997; 21: 72832.
  • 28
    Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal. Ann Surg. 2007; 248: 693701.